20-hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-κB activity by increasing IκBα levels in human keratinocytes

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Janjetovic, Zorica ^a   Zmijewski, Michal A ^a   Tuckey, Robert C ^b   DeLeon, Damon A ^a   Nguyen, Minh N ^b   Pfeffer, Lawrence M ^a   Slominski, Andrzej T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYCHOLECALCIFEROL; CALCITRIOL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; HYDROXYCOLECALCIFEROL; I KAPPA B; INTERLEUKIN 1ALPHA; MIXED FUNCTION OXIDASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; GENE ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; KERATINOCYTE; PROTEIN LOCALIZATION; REPORTER GENE; SKIN DISEASE; BIOLOGICAL MODEL; CHEMISTRY; CYTOLOGY; INFLAMMATION; METABOLISM; METHODOLOGY;

CELL PROLIFERATION; CHOLECALCIFEROL; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; HUMANS; HYDROXYCHOLECALCIFEROLS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; INFLAMMATION; INTERLEUKIN-1ALPHA; KERATINOCYTES; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; NF-KAPPA B; TRANSCRIPTION FACTORS;

EID: 67650102678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005988     Document Type: Article

References (74)

1. Lehmann B, Querings K, Reichrath J (2004) Vitamin D and skin: new aspects for dermatology. Exp Dermatol 13 Suppl 4: 11-15.
2. Holick MF (2003) Vitamin D: A millenium perspective. J Cell Biochem 88: 296-307.
3. Bikle (2006) Vitamin D: production, metabolism and mechanism of action. www.endotext.com.
4. Webb AR (2006) Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 92: 17-25.
5. Holick MF, Clark MB (1978) The photobiogenesis and metabolism of vitamin D. Fed Proc 37: 2567-2574.
6. Slominski A, Semak I, Zjawiony J, Wortsman J, Gandy MN, et al. (2005) Enzymatic metabolism of ergosterol by cytochrome p450scc to biologically active 17alpha,24-dihydroxyergosterol. Chem Biol 12: 931-939.
7. Slominski A, Semak I, Zjawiony J, Wortsman J, Li W, et al. (2005) The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. Febs J 272: 4080-4090.
8. Slominski A, Zjawiony J, Wortsman J, Semak I, Stewart J, et al. (2004) A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem 271: 4178-4188.
9. Tuckey RC, Janjetovic Z, Li W, Nguyen MN, Zmijewski MA, et al. (2008) Metabolism of 1alpha-hydroxyvitamin D3 by cytochrome P450scc to biologically active 1alpha,20-dihydroxyvitamin D3. J Steroid Biochem Mol Biol.
10. Tuckey RC, Li W, Zjawiony JK, Zmijewski MA, Nguyen MN, et al. (2008) Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc. Febs J 275: 2585-2596.
11. Tuckey RC, Nguyen MN, Slominski A (2008) Kinetics of vitamin D3 metabolism by cytochrome P450scc (CYP11A1) in phospholipid vesicles and cyclodextrin. Int J Biochem Cell Biol.
12. Slominski A, Semak I, Wortsman J, Zjawiony J, Li W, et al. (2006) An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2. Febs J 273: 2891-2901.
13. Tuckey RC (2005) Progesterone synthesis by the human placenta. Placenta 26: 273-281.
14. Lehmann B (2005) The vitamin D3 pathway in human skin and its role for regulation of biological processes. Photochem Photobiol 81: 1246-1251.
15. Zbytek B, Janjetovic Z, Tuckey RC, Zmijewski MA, Sweatman TW, et al. (2008) 20-Hydroxyvitamin D3, a Product of Vitamin D3 Hydroxylation by Cytochrome P450scc, Stimulates Keratinocyte Differentiation. J Invest Dermatol.
16. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700.
17. Bikle DD (2004) Vitamin D and skin cancer. J Nutr 134: 3472S-3478S.
18. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, et al. (2006) Vitamin D and cancer. J Steroid Biochem Mol Biol 102: 156-162.
19. van den Bemd GJ, Chang GT (2002) Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 3: 85-94.
20. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H, et al. (2006) Vitamin D and cancer. Anticancer Res 26: 2515-2524.
21. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266-281.
22. Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289: F8-28.
23. Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662-687.
24. Saito T, Okamoto R, Haritunians T, O'Kelly J, Uskokovic M, et al. (2008) Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol.
25. Holick MF (2003) Evolution and function of vitamin D. Recent Results Cancer Res 164: 3-28.
26. Bikle DD (2004) Vitamin D regulated keratinocyte differentiation. J Cell Biochem 92: 436-444.
27. Wiseman H (1993) Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. FEBS Lett 326: 285-288.
28. Holick MF (2003) Vitamin D deficiency: what a pain it is. Mayo Clin Proc 78: 1457-1459.
29. Bikle DD (2007) What is new in vitamin D: 2006-2007. Curr Opin Rheumatol 19: 383-388.
30. Bikle DD, Ng D, Tu CL, Oda Y, Xie Z (2001) Calcium- and vitamin D-regulated keratinocyte differentiation. Mol Cell Endocrinol 177: 161-171.
31. Holick MF (2000) Calcium and vitamin D. Diagnostics and therapeutics. Clin Lab Med 20: 569-590.
32. Bikle DD, Oda Y, Xie Z (2004) Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation. J Steroid Biochem Mol Biol 89-90: 355-360.
33. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
34. Van Waes C (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082.
35. Liu B, Xia X, Zhu F, Park E, Carbajal S, et al. (2008) IKKalpha is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell 14: 212-225.
36. Umezawa K (2006) Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci 97: 990-995.
37. Grone A (2002) Keratinocytes and cytokines. Vet Immunol Immunopathol 88: 1-12.
38. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M (2001) Keratins and the keratinocyte activation cycle. J Invest Dermatol 116: 633-640.
39. Banno T, Gazel A, Blumenberg M (2004) Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 279: 32633-32642.
40. Banno T, Gazel A, Blumenberg M (2005) Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 280: 18973-18980.
41. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
42. Du Z, Wei L, Murti A, Pfeffer SR, Fan M, et al. (2007) Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. J Cell Biochem 102: 1087-1094.
43. Wei L, Sandbulte MR, Thomas PG, Webby RJ, Homayouni R, et al. (2006) NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity. J Biol Chem 281: 11678-11684.
44. Yang CH, Murti A, Pfeffer LM (2005) Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J Biol Chem 280: 31530-31536.
45. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, et al. (1998) Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58: 2489-2499.
46. Pomerantz JL, Baltimore D (2002) Two pathways to NF-kappaB. Mol Cell 10: 693-695.
47. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352: 1899-1912.
48. Nagpal S (2003) An orphan meets family members in skin. J Invest Dermatol 120: viii-x.
49. Masuda S, Jones G (2006) Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 5: 797-808.
50. Bikle D, Teichert A, Hawker N, Xie Z, Oda Y (2007) Sequential regulation of keratinocyte differentiation by 1,25(OH)2D3, VDR, and its coregulators. J Steroid Biochem Mol Biol 103: 396-404.
51. Oda Y, Ishikawa MH, Hawker NP, Yun QC, Bikle DD (2007) Differential role of two VDR coactivators, DRIP205 and SRC-3, in keratinocyte proliferation and differentiation. J Steroid Biochem Mol Biol 103: 776-780.
52. Hawker NP, Pennypacker SD, Chang SM, Bikle DD (2007) Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J Invest Dermatol 127: 874-880.
53. Zella LA, Kim S, Shevde NK, Pike JW (2006) Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol Endocrinol 20: 1231-1247.
54. Lippens S, Denecker G, Ovaere P, Vandenabeele P, Declercq W (2005) Death penalty for keratinocytes: apoptosis versus cornification. Cell Death Differ 12 Suppl 2: 1497-1508.
55. Riis JL, Johansen C, Gesser B, Moller K, Larsen CG, et al. (2004) 1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch Dermatol Res 296: 195-202.
56. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S (2007) The antiinflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 103: 558-562.
57. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A (2006) Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant 21: 889-897.
58. Sun J, Kong J, Duan Y, Szeto FL, Liao A, et al. (2006) Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 291: E315-322.
59. Ren Q, Kari C, Quadros MR, Burd R, McCue P, et al. (2006) Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res 66: 5209-5215.
60. Bar M, Domaschke D, Meye A, Lehmann B, Meurer M (2007) Wavelength-dependent induction of CYP24A1-mRNA after UVB-triggered calcitriol synthesis in cultured human keratinocytes. J Invest Dermatol 127: 206-213.
61. Slominski AT, Zmijewski MA, Semak I, Sweatman T, Janjetovic Z, et al. (2009) Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin. PLoS ONE 4: e4309.
62. Zmijewski MA, Li W, Zjawiony JK, Sweatman TW, Chen J, et al. (2008) Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci 7: 1570-1576.
63. Zbytek B, Pfeffer LM, Slominski AT (2003) Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes. J Invest Dermatol 121: 1496-1499.
64. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26.
65. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, et al. (2001) An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 166: 7128-7135.
66. Zbytek B, Pfeffer LM, Slominski AT (2004) Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J Endocrinol 181: R1-7.
67. Reichrath J, Rappl G (2003) Ultraviolet light (UV)-induced immunosuppression: is vitamin D the missing link? J Cell Biochem 89: 6-8.
68. Lehmann B (1997) HaCaT cell line as a model system for vitamin D3 metabolism in human skin. J Invest Dermatol 108: 78-82.
69. Gurlek A, Pittelkow MR, Kumar R (2002) Modulation of growth factor/ cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev 23: 763-786.
70. Pisarchik A, Slominski A (2004) Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem 271: 2821-2830.
71. Hanissian SH, Akbar U, Teng B, Janjetovic Z, Hoffmann A, et al. (2004) cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP. Oncogene 23: 3700-3707.
72. Hanissian SH, Teng B, Akbar U, Janjetovic Z, Zhou Q, et al. (2005) Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma. Brain Res 1047: 56-64.
73. Zbytek B, Pfeffer LM, Slominski AT (2006) CRH inhibits NF-kappa B signaling in human melanocytes. Peptides 27: 3276-3283.
74. Pavicevic Z, Leslie CC, Malik KU (2008) cPLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells. J Lipid Res 49: 724-737.